

GLOBAL WHOLEHEALTH PARTNERS CORP

FORM 8-K (Current report filing)

Filed 04/05/21 for the Period Ending 03/21/21

| | |
|-------------|---|
| Address | 1402 N EL CAMINO REAL SAN CLEMENTE, CA, 92672 |
| Telephone | (714) 392-4112 |
| CIK | 0001598308 |
| Symbol | GWHP |
| SIC Code | 2835 - In Vitro and In Vivo Diagnostic Substances |
| Industry | Healthcare Facilities & Services |
| Sector | Healthcare |
| Fiscal Year | 06/30 |

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2021

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-56035
(Commission File Number)

46-2316220
(IRS Employer
Identification No.)

1402 N El Camino Real
San Clemente, CA
(Address of Principal Executive Offices)

92672
(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On March 21, 2021, Global Wholehealth Partners Corporation (the "Company") entered into a License Agreement ("Agreement") with Charles Strongo. Under the terms of the Agreement, the Company has the exclusive license to use the following items of intellectual property:

A Rapid, Micro-Welt or Later flow text for Parkinson's, Dementia, or Alzheimer or ASD - The test determines the level of the brain enzyme which has characteristics related to ASD Directly related to the hippocampus part of the brain (Autistic Syndrome Disorders), the lack of Top3B topoisomerases, seems to be a cause to the ASDs. The test is an enzyme test which is semi quantitative rapid test format.

The Company agreed to issue 5,000,000 shares of common stock and pay a 2% fee of gross sales from use of the patent. The duration of the agreement is for an initial period of five years commencing on March 21, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Registrant)

Date: April 5, 2021

By: /s/ Charles Strongo
Charles Strongo
Chief Executive Officer